These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
129 related articles for article (PubMed ID: 37844672)
1. Manufacturing dexamethasone intravitreal implants: Process control and critical quality attributes. Costello MA; Liu J; Wang Y; Qin B; Xu X; Li Q; Smith WC; Lynd NA; Zhang F Int J Pharm; 2023 Nov; 647():123515. PubMed ID: 37844672 [TBL] [Abstract][Full Text] [Related]
2. Role of PLGA Variability in Controlled Drug Release from Dexamethasone Intravitreal Implants. Costello MA; Liu J; Kuehster L; Wang Y; Qin B; Xu X; Li Q; Smith WC; Lynd NA; Zhang F Mol Pharm; 2023 Dec; 20(12):6330-6344. PubMed ID: 37955890 [TBL] [Abstract][Full Text] [Related]
3. Manufacturing of Dexamethasone-Poly(d,l-Lactide-co-Glycolide) Implants Using Hot-Melt Extrusion: Within- and Between-Batch Product Performance Comparisons. Kelley RA; Ghaffari A; Wang Y; Choi S; Taylor JR; Hartman RR; Kompella UB J Ocul Pharmacol Ther; 2020 Jun; 36(5):290-297. PubMed ID: 32330403 [No Abstract] [Full Text] [Related]
4. Drug release mechanisms of high-drug-load, melt-extruded dexamethasone intravitreal implants. Costello MA; Liu J; Chen B; Wang Y; Qin B; Xu X; Li Q; Lynd NA; Zhang F Eur J Pharm Biopharm; 2023 Jun; 187():46-56. PubMed ID: 37037387 [TBL] [Abstract][Full Text] [Related]
5. Reverse engineering the Ozurdex dexamethasone intravitreal implant. Costello MA; Liu J; Wang Y; Qin B; Xu X; Li Q; Lynd NA; Zhang F Int J Pharm; 2023 Mar; 634():122625. PubMed ID: 36690129 [TBL] [Abstract][Full Text] [Related]
6. Development of poly (lactic-co-glycolic acid) (PLGA) based implants using hot melt extrusion (HME) for sustained release of drugs: The impacts of PLGA's material characteristics. Yang F; Stahnke R; Lawal K; Mahnen C; Duffy P; Xu S; Durig T Int J Pharm; 2024 Sep; 663():124556. PubMed ID: 39122196 [TBL] [Abstract][Full Text] [Related]
7. Influence of the test method on in vitro drug release from intravitreal model implants containing dexamethasone or fluorescein sodium in poly (d,l-lactide-co-glycolide) or polycaprolactone. Stein S; Auel T; Kempin W; Bogdahn M; Weitschies W; Seidlitz A Eur J Pharm Biopharm; 2018 Jun; 127():270-278. PubMed ID: 29490233 [TBL] [Abstract][Full Text] [Related]
8. Influence of PLGA End Groups on the Release Profile of Dexamethasone from Ocular Implants. Saraf I; Kushwah V; Alva C; Koutsamanis I; Rattenberger J; Schroettner H; Mayrhofer C; Modhave D; Braun M; Werner B; Zangger K; Paudel A Mol Pharm; 2023 Feb; 20(2):1307-1322. PubMed ID: 36680524 [TBL] [Abstract][Full Text] [Related]
10. Hot-Melt Extrusion-Based Dexamethasone-PLGA Implants: Physicochemical, Physicomechanical, and Surface Morphological Properties and In Vitro Release Corrected for Drug Degradation. Ghaffari AA; Matter BA; Hartman RR; Bourne DWA; Wang Y; Choi S; Kompella UB Pharmaceutics; 2024 Jul; 16(7):. PubMed ID: 39065592 [TBL] [Abstract][Full Text] [Related]
11. Towards the optimization of drug delivery to the cochlear apex: Influence of polymer and drug selection in biodegradable intracochlear implants. Lehner E; Honeder C; Knolle W; Binder W; Scheffler J; Plontke SK; Liebau A; Mäder K Int J Pharm; 2023 Aug; 643():123268. PubMed ID: 37488058 [TBL] [Abstract][Full Text] [Related]
12. Protein release from poly(lactide-co-glycolide) implants prepared by hot-melt extrusion: thioester formation as a reason for incomplete release. Ghalanbor Z; Körber M; Bodmeier R Int J Pharm; 2012 Nov; 438(1-2):302-6. PubMed ID: 22989984 [TBL] [Abstract][Full Text] [Related]
13. Improved lysozyme stability and release properties of poly(lactide-co-glycolide) implants prepared by hot-melt extrusion. Ghalanbor Z; Körber M; Bodmeier R Pharm Res; 2010 Feb; 27(2):371-9. PubMed ID: 20033474 [TBL] [Abstract][Full Text] [Related]
14. Interdependency of protein-release completeness and polymer degradation in PLGA-based implants. Ghalanbor Z; Körber M; Bodmeier R Eur J Pharm Biopharm; 2013 Nov; 85(3 Pt A):624-30. PubMed ID: 23583495 [TBL] [Abstract][Full Text] [Related]
15. Reverse engineering of Perseris and development of compositionally equivalent formulations. Wang X; Bao Q; Wang R; Wan B; Wang Y; Qin B; Burgess DJ Int J Pharm; 2023 May; 639():122948. PubMed ID: 37044228 [TBL] [Abstract][Full Text] [Related]
16. Noninvasive characterization of the effect of varying PLGA molecular weight blends on in situ forming implant behavior using ultrasound imaging. Solorio L; Olear AM; Hamilton JI; Patel RB; Beiswenger AC; Wallace JE; Zhou H; Exner AA Theranostics; 2012; 2(11):1064-77. PubMed ID: 23227123 [TBL] [Abstract][Full Text] [Related]
17. Formulation and characterization of injectable poly(DL-lactide-co-glycolide) implants loaded with N-acetylcysteine, a MMP inhibitor. Desai KG; Mallery SR; Schwendeman SP Pharm Res; 2008 Mar; 25(3):586-97. PubMed ID: 17891553 [TBL] [Abstract][Full Text] [Related]
18. Antitumor Efficacy and Toxicity of 5-Fluorouracil-Loaded Poly(Lactide Co-glycolide) Pellets. Leelakanok N; Geary SM; Salem AK J Pharm Sci; 2018 Feb; 107(2):690-697. PubMed ID: 29031952 [TBL] [Abstract][Full Text] [Related]
19. PLGA-based monolithic filaments prepared by hot-melt extrusion: In-vitro comparative study. Kamel R; Abbas H Ann Pharm Fr; 2018 Mar; 76(2):97-106. PubMed ID: 29145995 [TBL] [Abstract][Full Text] [Related]
20. Complex sameness: Separation of mixed poly(lactide-co-glycolide)s based on the lactide:glycolide ratio. Skidmore S; Hadar J; Garner J; Park H; Park K; Wang Y; Jiang XJ J Control Release; 2019 Apr; 300():174-184. PubMed ID: 30853529 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]